top of page
Backgrounds.jpg

The voice of Colville and northeastern Washington since 1896

|

September 15, 2026

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

19.63 +0.18 (+0.93%)
Delayed Quote Updated: 12:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
20 21 Next >
News headline image
Earnings Scheduled For May 11, 2023 ↗
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its... 
Via Benzinga
News headline image
Takeda's FY22 Net Profit Jumps 38%, But Expects Lower FY23 Revenues ↗
Takeda Pharmaceutical Co Ltd's (NYSE: TAK) FY22 net profit rose 37.8% to ¥317.02 billion, mainly due to solid growth in its  
Via Benzinga
Takeda Pharmaceutical Ltd. (NYSE: TAK) Highlighted for Surprising Price Action
Via Investor Brand Network
News headline image
Takeda Delivers Strong Revenue and Profit Growth in FY2022; Updated Capital Allocation Policy Reflects Deleveraging Progress and Confidence in Growth Outlook
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Corza Medical Signs Definitive Agreement to Acquire Takeda's TachoSil Manufacturing Operations
From Corza Medical Inc.
Via GlobeNewswire
News headline image
Cannabis Movers & Shakers: Latest Appointments From Khiron, MariMed, Equilibria & More ↗
Equilibria Strengthens Women's Wellness With New CSO 
Via Benzinga
News headline image
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday ↗
The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases. 
Via The Motley Fool
News headline image
This Supercharged Dividend King Stock Might Soon Run Out of Steam ↗
Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025. 
Via The Motley Fool
News headline image
United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review ↗
The Pan American Health Organization (PAHO) is reportedly in early talks with Takeda Pharmaceutical Co Ltd (NYSE: TAK) regarding the potential orders of its dengue vaccine, TAK-003. 
Via Benzinga
News headline image
HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Takeda Receives FDA Approval to Expand the Use of HYQVIA® to Treat Primary Immunodeficiency in Children
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
We're starting off the day with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on Tuesday! 
Via InvestorPlace
News headline image
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
From Centogene NV
Via GlobeNewswire
News headline image
Zoetis Stock Shows Healthy Growth Along With Puppies, Kittens ↗
Zoetis stock is trying to complete a flat base with a 176.76 buy point. See if it can break out. Its stock got an upgrade Monday 
Via Investor's Business Daily
News headline image
Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal ↗
Duality Biologics out-licensed global rights (ex-China) for two ADC candidates to BioNTech, Pfizer’s partner, for one of the two original COVID-19 vaccines in a deal worth $170 million upfront and up... 
Via Talk Markets
News headline image
The Byzantine Adderall Shortage Puts Teva And Others In The Hot Seat ↗
Millions of people are scrambling to get their ADHD medication. Here's why. 
Via Investor's Business Daily
News headline image
Etsy To Rally Around 30%? Here Are 10 Other Analyst Forecasts For Tuesday ↗
B of A Securities cut the price target for Stem, Inc. (NYSE: STEM) from $9 to $5. B of A Securities analyst Julien Dumoulin-Smith downgraded the stock from Neutral to Underperform. Stem shares fell... 
Via Benzinga
News headline image
Takeda Announces New U.S. Corporate Social Responsibility (CSR) Program Partners
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Takeda Announces Results From Phase 4 Vedolizumab Study in Patients With Chronic Pouchitis Published in New England Journal of Medicine
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Zoetis Stock Sees IBD Relative Strength Rating Improve To 73 ↗
Zoetis stock had its Relative Strength Rating upgraded to 73 Monday -- a nice improvement, but still shy of the 80-plus score you look for. 
Via Investor's Business Daily
News headline image
BioLife Plasma Services Opens its 200th Plasma Donation Center in the U.S.
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Week In Review: HighlightLL Pharma Out-Licenses Parkinson's Treatment To Biohaven For $970 Million ↗
HighlightLL Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven’s Biohaven in a deal worth up to $970 million. Biohaven will have global rights to the product... 
Via Talk Markets
News headline image
Price Growth & Yield: For That Magical Combo, Leave the U.S.
Three foreign stocks, Takeda Pharmaceutical, United Microelectronics, and Coca-Cola FEMSA are showing that magical combination of growth and yield. 
Via MarketBeat
News headline image
Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says ↗
 
Via Benzinga
News headline image
Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) Sets New 52-Week High in Friday Session
Via Investor Brand Network
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2023 ↗
 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page